Benign neoplasm of other and unspecified parts of small intestine
ICD-10 D13.3 is a billable code used to indicate a diagnosis of benign neoplasm of other and unspecified parts of small intestine.
D13.3 refers to benign neoplasms located in the small intestine that are not classified elsewhere. These neoplasms can arise from various tissues within the small intestine, including epithelial, mesenchymal, and neuroendocrine tissues. Common types of benign neoplasms in this region include adenomas, lipomas, and gastrointestinal stromal tumors (GISTs). While benign, these neoplasms can lead to complications such as obstruction, bleeding, or intussusception, necessitating careful monitoring and management. Surveillance is crucial, particularly if the neoplasm is symptomatic or if there is a family history of gastrointestinal cancers. Although benign neoplasms are not cancerous, there is a potential for malignant transformation, especially in cases of adenomatous polyps. Regular follow-up with imaging studies or endoscopic evaluations may be warranted to assess for changes in size or characteristics that could indicate a risk of malignancy.
Detailed descriptions of the neoplasm's size, location, and symptoms, along with imaging or biopsy results.
Patients presenting with abdominal pain, gastrointestinal bleeding, or incidental findings on imaging.
Documentation should clearly indicate the benign nature of the neoplasm and any surveillance recommendations.
Operative reports detailing the excision of the neoplasm, histopathology results, and follow-up care plans.
Surgical intervention for symptomatic benign neoplasms or those with potential for malignant transformation.
Ensure that the surgical indication is well-documented to support the coding of D13.3.
Used when a patient with a known benign neoplasm undergoes surveillance colonoscopy.
Documentation must include indications for the procedure and findings related to the neoplasm.
Gastroenterologists should ensure that the reason for surveillance is clearly documented.
Accurate coding of D13.3 is crucial for proper reimbursement, tracking of benign neoplasms, and ensuring appropriate surveillance and management strategies are implemented for patients.
